深圳市药欣生物科技

Pharmacin (Shenzhen Pharmacin Co., Ltd.) is an innovative clinical-stage biopharmaceutical company founded in 2016 and headquartered in Shenzhen, China, with subsidiaries in Suzhou, China, and New Haven, Connecticut, USA. The company focuses on developing best-in-class therapeutics and high-end modified formulations (505(b)(2) pathway) to address unmet medical needs in oncology, immunology, and infectious diseases. Pharmacin leverages its proprietary formulation platforms, such as SprāSol® for amorphous solid dispersions, to significantly improve the bioavailability and solubility of poorly soluble small molecules and PROTACs. Its clinical pipeline includes candidates for breast cancer, anaphylaxis, chronic myelogenous leukemia, and plaque psoriasis, with several programs currently in Phase 1 and Phase 2 clinical trials.